Methotrexate/mifepristone-combined with embryo removal in the treatment of caesarean scar pregnancy
Methotrexate/mifepristone-combined with embryo removal in the treatment of caesarean scar pregnancy
复制标题
DOI：
10.26355/eurrev_202203_28347
复制
发表时间：
2022-01-01
影响因子：
3.3
通讯作者：
Zhou, Q.
中科院分区：
文献类型：
--
作者：
Yu, S-S;Ma, M-Y;Zhou, Q.
目的：比较甲氨蝶呤(MTX)/甲氨喋呤(MIFE)-普鲁司通不同给药方式在初始用药阶段的疗效。方法：对2015年1月至2021年7月收治的66例剖宫产瘢痕妊娠患者的临床资料进行回顾性分析，将患者分为三组：米非司酮组14例，甲氨蝶呤+米非司酮组29例，甲氨蝶呤/米非司酮联合组23例。对基本发现进行了分析。以及三组间的疗效比较。结果：两组患者在胎龄、住院天数、费用、子宫肌层厚度等方面差异有统计学意义。心脏活动度和组间平均囊径(p
OBJECTIVE: The aim of this study was to compare the effect of different administration modalities of methotrexate (MTX)/mife-pristone in the initial medication stage. followed by embryo transfer in the treatment of caesarean scar pregnancy (CSP).PATIENTS AND METHODS: A retrospective analysis of 66 CSP patients who received treatment in our hospital from January 2015 to July 2021 was performed, and participants were divided into three groups: Group one (n=14) received mifepristone followed by embryo removal treatment, Group two (n=29) received MTX followed by embryo removal, and Group three (n=23) received a methotrexate/mifepristone combined treatment followed by embryo removal. The basic findings were analysed. along with the curative effects between the three groups. Risk factors predicting additional treatment after initial intervention failure were analysed.RESULTS: There were statistically significant differences in gestational age, hospitalization days, costs, myometrial thickness. cardiac activity, and mean sac diameter between groups (p